Toggle Main Menu Toggle Search

Open Access padlockePrints

5% Carbon Dioxide is safe but of limited efficacy as a treatment for paediatric non-convulsive status epilepticus: An open label observational study

Lookup NU author(s): Dr Rob ForsythORCiD, Dr Ming Lai, Dr Vanessa Hogan



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).


Objective: To establish the efficacy and tolerability of inhaled 5% carbon dioxide/95% oxygen as a treatment for paediatric non-convulsive status epilepticus (NCSE).Methods: In an open label clinical trial, children in NCSE were given high flow inhaled 5% carbon dioxide/95% oxygen by face mask for 120 s under EEG control.Results: Six children (five male; ages 3-13; all with severe underlying epilepsy and disability) were recruited. Inhalation was well tolerated in all cases. Capillary blood gasses showed no significant derangements at the end of the inhalation. Effects on EEG normalisation were limited and transient, and no clinical improvements were noted. No adverse effects occurred.Conclusion: Inhaled 5% carbon dioxide/95% oxygen has been suggested as a potent, well tolerated anticonvulsant. An anticonvulsant without sedating and respiration-depressing effects would be particularly welcome in the management of NCSE where the justification for aggressive anticonvulsant therapy is often uncertain, however it appears that 5% carbon dioxide is of limited efficacy in this context. (C) 2016 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Publication metadata

Author(s): Forsyth R, Martland T, Lai M, Vadlamani G, Hogan V

Publication type: Article

Publication status: Published

Journal: European Journal of Paediatric Neurology

Year: 2016

Volume: 20

Issue: 4

Pages: 560-565

Print publication date: 01/07/2016

Online publication date: 22/04/2016

Acceptance date: 06/04/2016

Date deposited: 17/08/2016

ISSN (print): 1090-3798

ISSN (electronic): 1532-2130

Publisher: Elsevier


DOI: 10.1016/j.ejpn.2016.04.001


Altmetrics provided by Altmetric


Funder referenceFunder name
P1103Epilepsy Research UK